Tumor News and Research

RSS

COMET trial shows active monitoring is noninferior to standard treatment for low-risk DCIS

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as those who underwent guideline-concordant treatment, according to results from the COMET clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

Tamoxifen lowers breast cancer recurrence in good-risk DCIS patients

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the same breast, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

12 Dec 2024

Study sheds light on how deep sleep supports memory formation

It has been known for nearly 20 years that slow, synchronous electrical waves in the brain during deep sleep support the formation of memories.

12 Dec 2024

Exosomes: A double-edged sword in hepatocellular carcinoma

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of tumorigenesis, the TIME attempts to eliminate abnormal cells through immune surveillance.

11 Dec 2024

Caltech develops microrobots for precise drug delivery

In the future, delivering therapeutic drugs exactly where they are needed within the body could be the task of miniature robots. Not little metal humanoid or even bio-mimicking robots; think instead of tiny bubble-like spheres.

11 Dec 2024

Next-generation cell-penetrating antibodies could transform cancer treatment

A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" by Rackear et al. was published in Oncotarget's Volume 15 on November 22, 2024, titled "Advancements in cell-penetrating monoclonal antibody treatment."

11 Dec 2024

Understanding how angiogenesis contributes to drug resistance in breast cancer

Breast cancer, the most common cancer among women, is notorious for its ability to develop resistance to a wide range of treatments, including surgery, chemotherapy, targeted therapies, and immunotherapy.

11 Dec 2024

FunMap reveals new insights into cancer-associated genes and proteins

Large-scale protein and gene profiling have massively expanded the landscape of cancer-associated proteins and gene mutations, but it has been difficult to discern whether they play an active role in the disease or are innocent bystanders.

11 Dec 2024

TCR sequencing sheds light on tumor immune interactions in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

11 Dec 2024

Prostate cancer vaccines: Progress, challenges, and future directions

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in clinical effectiveness and validation.

11 Dec 2024

Metabolic imaging detects ovarian cancer subtypes and predicts chemotherapy response

Study demonstrates how metabolic imaging differentiates high and low oxidative phosphorylation (OXPHOS) subtypes of high-grade serous ovarian cancer (HGSOC). By assessing metabolic activity, it also identifies early and variable responses to chemotherapy, improving precision in treatment strategies.

10 Dec 2024

Study links Western diet to chronic inflammation and colorectal cancer growth

Colorectal cancer, the second leading cause of cancer-related deaths in the United States, may be fueled by the food on our plates.

10 Dec 2024

New $1.4M grant supports innovative kidney cancer treatment strategy

Weill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.

10 Dec 2024

Scientists uncover genetic code driving tumor formation and spread

A group of scientists at VCU Massey Comprehensive Cancer Center has revealed a new genetic code that acts like a cancer ringleader, recruiting and deploying a gang of tumor cells to incite a biological turf war by invading healthy organs and overpowering the normal cells.

9 Dec 2024

Study provides the first evidence of genetic predisposition to breast cancer metastasis

Ninety percent of cancer deaths are due to the spread of cancer, not complications from the original tumor.

9 Dec 2024

47th annual San Antonio Breast Cancer Symposium kicks off in December

Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), in partnership with the American Association for Cancer Research (AACR), is hosting the 47th annual San Antonio Breast Cancer Symposium at the Henry B. Gonzalez Convention Center on Dec. 10-13.

9 Dec 2024

Lab-grown tumor organoids predict patient response to CAR T cell therapy

For the first time, researchers used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to accurately model a patient's response to CAR T cell therapy in real time.

9 Dec 2024

Soft tissue sarcoma rates vary between active-duty military servicemen and general population

A recent analysis reveals that the incidence rates of soft tissue sarcomas - cancers in muscle, fat, blood vessels, nerves, and tendons - are lower in young U.S. active-duty military servicemen compared with those in the general population, but higher in middle-aged servicemen, perhaps due to greater cumulative exposure to toxins.

9 Dec 2024

New immunotherapeutic platform improves mRNA therapy efficacy against cancer

Therapeutic mRNAs offer great potential as a versatile and precise tool against cancer and other diseases.

9 Dec 2024

Antibody trials show encouraging results in patients with high-risk forms of two blood cancers

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.

9 Dec 2024